ReviewFrontiers in immunology2026
The crucial role of N6-methyladenosine modification in acute kidney injury: mechanisms and therapeutic potential.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a clinically critical condition with a high mortality rate. Its complex pathophysiological mechanisms remain incompletely understood, and there is a lack of effective targeted therapeutic strategies. In recent years, the role of epigenetic modifications in the initiation and progression of kidney disease has been increasingly clarified. N6-methyladenosine (m6A) is one of the most important and common post-transcriptional modifications among various RNAs, including eukaryotic mRNAs, lncRNAs, and miRNAs. It is dynamically and reversibly regulated by methyltransferases ('writers'), demethylases ('erasers'), and binding proteins ('readers') to modulate processes such as RNA splicing, export, stability, translation, and degradation. This modification exerts diverse biological effects and is extensively involved in both physiological and pathological pathways. Recently, a growing body of evidence has indicated that m6A modification plays a crucial regulatory role in the development and progression of AKI. Existing studies suggest that m6A modification profoundly influences the fate of renal tubular epithelial cells (TECs) by regulating the expression of genes associated with inflammatory responses and programmed cell death, thereby modulating the severity of AKI and the subsequent renal repair process. This review systematically summarizes the latest research advances regarding m6A modification in AKI, elucidates the mechanisms by which it influences the pathogenesis of AKI through various cellular processes, and explores the potential of m6A-targeted therapies for treating AKI, thereby providing insights into the regulatory networks of m6A modification in AKI and the epigenetic regulation of transcription in this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.